FAMAR expands manufacturing footprint into North America

Famar today announces the closing of the acquisition of a manufacturing site from Bayer, located at Pointe-Claire, Canada, with the transfer of full ownership of the plant to Famar. Pointe Claire is the first facility and FDA-approved site for Famar in North America. The site employs 150 people and offers excellent capability for the manufacture of liquid, semi-solid and solid dosage forms.  The new Pointe-Claire site will be operated by Famar Montreal Inc.

With this acquisition, Famar is expanding its manufacturing footprint into North America, building on its existing strong presence in E.U with 11 sites and 3.200 employees. Jeffrey Morrod, CEO of Famar, said “This is an important step for Famar, pursuing its strategy of continued organic and inorganic growth with expansion into North America through the acquisition of an FDA-approved facility. There is strong interest in this acquisition from existing customers and the potential for new partnerships which demonstrate that Famar is on a path to growth into North America. This acquisition also reinforces our strong partnership with BAYER.”

Famar is a leading contract manufacturing organization serving the pharmaceutical and health & beauty markets, supplying the industry with a wide range of products and serving most international markets with a broad customer base.  With 11 sites across Europe Famar has a significant footprint in the European pharmaceutical CDMO sector.

For further information, please visit: http://www.famar.eu

Media contact: ob@addingvalueconseils.com

In our website we use cookies enabling page navigation and access to specific website areas. Those cookies are necessary for the proper functioning of the website. We use as well statistic cookies that collect and report anonymous information, helping us to understand how visitors interact with our website. By clicking on the “I accept” button you agree on our use of cookies. If you require further information or don’t intend to accept our cookies, you can visit the “Term of use” page.